Status:
COMPLETED
Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention
Lead Sponsor:
Bayside Health
Collaborating Sponsors:
Novartis
Conditions:
Osteopenia
Complications of Heart-lung Transplant
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this trial is to see whether zoledronic acid is better than pamidronate to treat low bone density in heart and lung transplant patients.
Eligibility Criteria
Inclusion
- reduced bone density as indicated by a bone density T score \<-1.in either the lumbar spine or femoral neck
- have undergone or are on the waiting list for heart or lung transplantation
- are receiving adequate calcium and vitamin D therapy
- have provided written informed consent prior to participation in the trial
Exclusion
- untreated hypogonadism, hypothyroidism or hyperthyroidism
- acute or major organ rejection or intercurrent illness
- pregnancy or breastfeeding
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00164008
Start Date
October 1 2002
End Date
December 1 2005
Last Update
December 5 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.